Literature DB >> 9674201

[Hemolytic uremic syndrome in children of Mendoza, Argentina: association with Shiga toxin-producing Escherichia coli infection].

M Rivas1, L Balbi, E S Miliwebsky, B García, M I Tous, N A Leardini, M A Prieto, G M Chillemi, M E de Principi.   

Abstract

Shiga toxin-producing Escherichia coli (STEC) has been associated with pathogenesis of hemolytic uremic syndrome (HUS) worldwide. The aim of the present study was to characterize the HUS cases reported in Mendoza and to determine their association with STEC infection. From July 1994 through June 1996 thirty-six patients with HUS were admitted to Hospital Pediátrico "Dr. HJ Notti" (Mean age 22.8 +/- 14.9 months, 44% females). The children developed HUS following an acute diarrheal illness in 94.4% of the cases. Bloody diarrhea was observed in 83.3% of them. Antimicrobial therapy had been administered to 69.4% of the patients. Most of the patients were well-nourished (88.9%), belong to middle-low socioeconomical condition (91.7%), from urban areas (72.2%) and they were mostly assisted during summer and the beginning of autumn. The acute stage of the disease occurred with presentation of pallor (100%), edema (25%), anuria (38.9%), oliguria (41.7%), hemolytic anemia (97.2%), thrombocytopenia (86.1%) and neurological involvement (41.7%). Twenty-five of them presented the full clinical syndrome. Peritoneal dialysis were performed in 50% and packed blood cell transfusion in 88.9%. The mean days of hospitalization was 15.1 +/- 9.2 [range 1-32]. A 91.7% of the patients recovered renal function, two developed chronic renal failure and one died. Cumulative evidence of STEC infection was found in 19 (86.4%) of 22 HUS patients. STEC O157:H7, biotype C was found in 8 (36.4%). The prevalent Stx type was Stx2 in STEC, free fecal Stx (STMF) and Stx-neutralizing antibodies (a-Stx). In Mendoza, as in the rest of Argentina E. coli O157:H7, biotype C, Stx2 producer is the most frequently detected pathogen in HUS cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674201

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  7 in total

1.  Effect of Shiga toxin 2 on water and ion transport in human colon in vitro.

Authors:  P Fiorito; J M Burgos; M F Miyakawa; M Rivas; G Chillemi; D Berkowski; E Zotta; C Silberstein; C Ibarra
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

2.  The occurrence of Shiga toxin-producing Escherichia coli in bathing water of the Sierra de la Ventana region, Buenos Aires Province, Argentina.

Authors:  Patricia L Marucci; Nelda L Olivera; Lorena I Brugnoni; Maria G Sica; Maria Amelia Cubitto
Journal:  Environ Monit Assess       Date:  2010-05-15       Impact factor: 2.513

3.  Virulence genotypes and serotypes of verotoxigenic Escherichia coli isolated from cattle and foods in Argentina. Importance in public health.

Authors:  A E Parma; M E Sanz; J E Blanco; J Blanco; M R Viñas; M Blanco; N L Padola; A I Etcheverría
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

4.  First Shiga toxin-producing Escherichia coli isolate from a patient with hemolytic uremic syndrome, Brazil.

Authors:  Beatriz Ernestina C Guth; Renato Lopes de Souza; Tânia Mara I Vaz; Kinue Irino
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

5.  Development of an experimental hemolytic uremic syndrome in rats.

Authors:  Elsa Zotta; Nestor Lago; Federico Ochoa; Horacio A Repetto; Cristina Ibarra
Journal:  Pediatr Nephrol       Date:  2008-02-06       Impact factor: 3.714

6.  Molecular characterization of Verocytotoxigenic Escherichia coli O157:H7 isolates from Argentina by Multiple-Loci VNTR Analysis (MLVA).

Authors:  Ana V Bustamante; Paula M A Lucchesi; Alberto E Parma
Journal:  Braz J Microbiol       Date:  2009-12-01       Impact factor: 2.476

7.  Risk factors for sporadic Shiga toxin-producing Escherichia coli infections in children, Argentina.

Authors:  Marta Rivas; Sergio Sosa-Estani; Josefa Rangel; Maria G Caletti; Patricia Vallés; Carlos D Roldán; Laura Balbi; Maria C Marsano de Mollar; Diego Amoedo; Elizabeth Miliwebsky; Isabel Chinen; Robert M Hoekstra; Paul Mead; Patricia M Griffin
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.